Two good tools with different bets
Whether you typed Rayyan vs Covidence or Covidence vs Rayyan, the question is the same. These are the two names most systematic reviewers hear first, and both do the core job well: they get two people through thousands of titles and abstracts without stepping on each other's decisions. The real differences are price, how far past screening each one goes, and who it is built for.
Pricing as of 2026
Rayyan has a genuinely free tier with no time limit: up to 3 active reviews, 2 invited co-reviewers, basic duplicate detection, AI relevance predictions, and limited mobile app access. Paid individual plans (currently packaged as Essential and Advanced) work out to about 60 to 100 USD per seat per year, and institutional plans are custom priced.
Covidence sells access per review: a personal plan costs about 340 USD per year for a single review, or about 900 USD per year for a package of three, on 12-month terms. Its main sales channel is institutional licensing, and many university libraries hold a campus license. If yours does, the price comparison mostly disappears.
Title and abstract screening
Both tools handle blinded dual review properly. In Covidence every study collects two votes, reviewers cannot see each other's votes until both are in, and disagreements land in a dedicated conflict queue. Rayyan offers blind mode on every plan, surfaces conflicts when you unblind, and adds AI relevance predictions. Day to day, both are fast, and neither will slow a trained team down.
Deduplication
Covidence deduplicates automatically on every import. Its matcher is strict, so some near-duplicates still need manual handling, but the default behavior is hands-off. Rayyan detects duplicates on the free tier, while the auto-resolver that clears them in bulk is a paid feature, so free-tier users resolve duplicates one by one.
Full text, extraction, and quality assessment
This is where the two products separate. Covidence carries the review further: a dedicated full-text stage, two data extraction modules (the older one exports to RevMan, the newer one offers fully customizable templates but cannot export to RevMan), Cochrane risk-of-bias templates, auto-generated PRISMA flow diagrams, and exports to RevMan, EndNote, Zotero, RIS, CSV, and Excel. Rayyan has closed some of this gap but not all of it: PRISMA diagrams require a paid plan, data extraction is limited to PICO-style extraction on the higher tier, and there is no built-in risk-of-bias workflow comparable to Covidence's. Note that neither tool runs a meta-analysis. Covidence expects you to export extracted data to RevMan or a spreadsheet for the statistics.
Screening on the go
Rayyan has a mobile app, limited on the free tier and unlimited on paid plans, so screening can continue away from a desk. If phone screening matters to you, this is a clear point for Rayyan.
Verdicts by scenario
- Solo student on a budget: Rayyan. The free tier covers 3 active reviews with a co-reviewer, and the paid plan is about 60 USD per year if you need PRISMA diagrams and duplicate auto-resolve.
- Funded team at an institution with a license: Covidence. The blinded voting, conflict queue, extraction templates, and RevMan-friendly exports fit a Cochrane-style team workflow, and a campus license removes the cost objection.
- Review that ends at screening: either works, so pick the one your team already knows. Review that continues to analysis: Covidence gets you further, but you will still export to RevMan or R for the pooled numbers.
A third option: free, and it keeps going after screening
Covexe covers the same screening ground for free: blinded dual screening with a conflict resolver and Cohen's kappa, deduplication on DOI and PMID with every pair reviewed before it is dropped, and a full-text stage with exclusion reasons. It also includes extraction templates, risk of bias (RoB 2, ROBINS-I, NOS, JBI, AXIS), and a PRISMA flow diagram counted from your screening decisions. Then it goes where neither tool does: meta-analysis validated against R's metafor and GRADE certainty ratings, all in one project. If you were leaning Rayyan for the price, see the Rayyan alternative page; if you were leaning Covidence for the pipeline, see the Covidence alternative page.